WO2001066171A1 - Nouveau filtre pour leucopherese - Google Patents
Nouveau filtre pour leucopherese Download PDFInfo
- Publication number
- WO2001066171A1 WO2001066171A1 PCT/JP2001/001880 JP0101880W WO0166171A1 WO 2001066171 A1 WO2001066171 A1 WO 2001066171A1 JP 0101880 W JP0101880 W JP 0101880W WO 0166171 A1 WO0166171 A1 WO 0166171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- structural unit
- group
- leukocyte removal
- hydrophobic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
- A61M1/3633—Blood component filters, e.g. leukocyte filters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1669—Cellular material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1669—Cellular material
- B01D39/1676—Cellular material of synthetic origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0439—White blood cells; Leucocytes
Definitions
- the present invention relates to a blood filter for efficiently removing leukocytes. More specifically, the present invention relates to a leukocyte removal filter that selectively removes only leukocytes from a leukocyte-containing liquid such as whole blood, and easily transmits erythrocytes, plasma and platelets.
- leukocyte removal technology has been highlighted as one of the most important technical issues with the aim of reducing the physical burden on patients after blood transfusion, and many studies have been conducted.
- leukocytes are the main factor causing graft-versus-host reaction (GVHD), non-hemolytic pyrogenic ⁇ 'J action.
- GVHD graft-versus-host reaction
- leukocytes are removed or inactivated by centrifugation, filtration, or irradiation.
- the removal of leukocytes by filtration has been widely practiced as an effective method that can be easily carried out even on a bedside because it is simple and low-loss.
- leukocyte removal technology Another importance of leukocyte removal technology is to improve the storage stability and safety of blood products used for component transfusion. In other words, if the storage period of a blood product containing leukocytes becomes longer, it will not be possible to prevent the exothermic site force produced by leukocytes during storage, and further, the leukocytes containing viruses and bacteria will die. ⁇ It is extremely difficult to prevent adverse effects such as crushing and diffusion of pathogenic media into blood products. Therefore, it has been pointed out that it is necessary to remove leukocytes from blood products before storage as much as possible.
- the blood (whole blood) collected from the supplier is separated into components by centrifugation, and the leukocytes are further removed from the obtained blood products. Operation was necessary.
- This conventional method in addition to the complexity of separation and purification operations and economic problems, also has undesired problems such as damage to blood cells, elution of harmful components from leukocytes, and contamination with bacteria. Point was included.
- leukocytes such as whole blood Selective removal of contaminating leukocytes from blood components including blood and platelets, and platelets cannot be recovered with high efficiency.Selective removal of only leukocytes directly from whole blood, and red blood cells
- these methods require special equipment (radiation, electron beam irradiation equipment, etc.) for the graft reaction, and when the irradiation time and intensity are adjusted to increase the graft rate.
- it has essential problems such as elution due to the decomposition of the base material, and has not been a material that can be industrially satisfied in the medical field in terms of process, safety, and cost.
- the present invention provides a leukocyte removal filter that selectively removes only leukocytes from whole blood, blood components containing leukocytes and platelets, and recovers red blood cells and plasma, especially platelets, with low adhesion of platelets.
- the task is to do.
- the present inventors have conducted intensive studies focusing on the behavior of each component contained in whole blood with respect to a porous filter, in particular, on the leukocyte removal characteristics during filtration of whole blood and the adhesion or permeation behavior of platelets.
- a blood filter composed of a polymer (A component) containing a hydrophobic structural unit and a hydrophilic structural unit and a porous substrate (B component) achieves both high leukocyte removal ability and high platelet recovery ability.
- a component containing a hydrophobic structural unit and a hydrophilic structural unit and a porous substrate (B component)
- the polymer containing a hydrophobic structural unit and a hydrophilic structural unit in the present invention is, for example, one or two or more types of hydrophobic structural units represented by the following general formulas (1) to (4). both a polymer containing more than one unit t
- R 1 to R 9 are each independently hydrogen, a halogen atom, an alkyl group having 1 to 12 carbon atoms, an aromatic compound having 6 to 12 carbon atoms, and a heterocyclic compound having 5 to 12 carbon atoms. Macromer with a number average molecular weight of 500 to 500
- the hydrophobic structural unit in the present invention is a hydrophobic monomer unit represented by any of the general formulas (1) to (4), and this structure can be introduced into a polymer chain by any conventionally known method.
- Good for example, a method of combining a hydrophobic monomer and a hydrophilic monomer, homopolymerization of a macromer containing a hydrophobic structural unit and a hydrophilic structural unit, or a macromer having a hydrophobic structural unit and a hydrophilic monomer or a hydrophilic structural unit Copolymerizing a hydrophilic monomer with homopolymer, and then grafting a hydrophobic monomer to a part of the polymer chain, homopolymerizing the hydrophilic monomer, and then terminating the end of the polymer chain A method of adding a hydrophobic monomer.
- a part of the polymer chain is modified or chemically modified (esterification, amidation, alkylation, halogenation, hydrogenation, etc.) to make it hydrophobic.
- the method of introducing structural units can be exemplified, and the optimal method can be selected in a timely manner according to the purpose, reaction conditions, process, cost, etc.
- the arrangement of the hydrophobic structural units in the polymer chain of the polymer as component A It may be in any form, such as a system, alternating, block, or graft, and is not particularly limited.
- hydrophobic monomer unit represented by any of the general formulas (1) to (4) is a structural unit having a crosslinkable functional group
- two or more molecules are crosslinked by a crosslinking reaction after the introduction of the structural unit.
- the chemical structure formed by the reaction of the acidic functional group is also a hydrophobic structural unit of the present invention, and the hydrophobic structural unit like the parentheses satisfies both high leukocyte removing ability and platelet collecting ability in the present invention. It is one of the most preferred structures for.
- the hydrophilic structural unit in the present invention is, for example, a hydrophilic monomer unit represented by the general formula (5).
- R 1 Q to R 14 are each independently hydrogen or an alkyl group having 1 to 9 carbon atoms. However, at least one of R 11 and R 12 is an alkyl group. ]
- the hydrophobic structural units in the polymers represented by the general formulas (1) to (4) have hydrophobic interactions. Effectively acts on leukocyte removal performance, while the non-thionionic and highly hydrophilic hydrophilic structural units represented by the general formula (5) act to suppress platelet adhesion. It is considered that the combination of high leukocyte removal and efficient platelet recovery was achieved.
- the details of the present invention will be specifically described below.
- the leukocyte removal filter of the present invention refers to leukocyte blood, such as whole blood. This means a porous filter that selectively removes only white blood cells from blood components including platelets and collects platelets with high efficiency.
- the hydrophobic structural unit in the polymer (A component) of the present invention is a structural unit represented by the following general formulas (1) to (4) or derivatives thereof, wherein the hydrophobic structural unit has a crosslinkable functional group. If it has, the molecular structure of the crosslinking point after the crosslinking reaction is also within the range of the hydrophobic structural unit of the present invention.
- R to 9 are each independently hydrogen, a halogen atom, an alkyl group having 1 to 12 carbon atoms, an aromatic compound having 6 to 12 carbon atoms, a heterocyclic compound having 5 to 12 carbon atoms, Macromers and / or carboxylic acid groups, carbonyl groups, acid anhydride groups, carboxylic acid ester groups, epoxy groups, ether groups, carbonate groups, sulfonic acids, sulfonic acids having an average molecular weight of 500 to 500,000
- hydrophobic structural units represented by the general formulas (1) to (4) have a hydrophilic group as a functional group, it is sufficient that the entire structural unit is hydrophobic.
- the hydrophobic structural unit in the component A of the present invention is a hydrophobic monomer unit represented by any one of the general formulas (1) to (4) or a derivative thereof.
- the derivative is a reaction between the hydrophobic structural units. Substance or functional group in hydrophobic structural unit And a reaction product with other functional groups in the polymer.
- hydrophobic structural units can be introduced into the polymer (component A) by copolymerizing a hydrophobic monomer and a hydrophilic monomer, by homopolymerizing a macromer containing a hydrophobic structural unit and a hydrophilic structural unit, or A method of copolymerizing a macromer having a hydrophilic structural unit with a hydrophilic monomer or a macromer having a hydrophilic structural unit, a method of homopolymerizing a hydrophilic monomer and then removing a hydrophobic monomer to a part of a polymer chain, A method of adding a hydrophobic monomer to the end of a polymer chain after homopolymerizing a hydrophilic monomer, and modifying or chemically modifying a part of the polymer chain (alkylation, halogenation, A known method such as a method of introducing a hydrophobic structural unit by hydrogenation or the like can be arbitrarily selected and employed.
- Preferred examples of the crosslinkable functional group to be introduced into the polymer (component A) of the present invention include an alkoxysilane group and derivatives thereof, an isocyanate group, an epoxy group (daricidyl group), and an acid anhydride group. be able to.
- an alkoxysilane group is preferable in terms of reactivity, and more specifically, a trimethoxysilane group or a triethoxysilane group is a particularly preferable crosslinkable functional group. Examples can be given.
- One or two or more of these crosslinkable functional groups may be introduced into the polymer chain, and are not particularly limited.
- hydrophobic monomer for forming the hydrophobic structural unit represented by the general formulas (1) to (4) of the present invention examples include, for example, ethylene, propylene, 1-butene, cyclopentene, norpolpolene and the like.
- esters such as methacrylate acrylate, acrylate esters, and cyclic siloxanes.
- hydrophobic monomer having a crosslinkable functional group examples include ⁇ -methacryloxy lip mouth bil-trimethoxysilane, glycidyl methacrylate, and methacryloxypropyl succinate. it can.
- ester-based monomers such as methacrylic acid or acrylate alkyl esters
- methacryloleic acid ester and atalinoleic acid ester are preferred hydrophobic monomers in the present invention.
- It is a functional monomer.
- 2-hydroxypropyl methacrylate, methyl atalylate, methyl methacrylate, etinoleata acrylate, ethyl methacrylate, petit / real acrylate, petitzole methacrylate, 2-ethyl methacrylate Hexinoleacrylate and 2-ethylhexyl methacrylate can be mentioned as particularly preferred hydrophobic monomers.
- hydrophobic monomers can be used alone or as a mixture of two or more.
- hydrophobic monomers there can be exemplified 2-hydroxypropylmethacrylate, methinolemethacrylate, etizolemetacrylate, and petitnomethacrylate.
- examples of the most preferred hydrophobic monomers in the present invention include 2-hydroxypropyl methacrylate and methinolemethacrylate.
- hydrophobic monomer has a crosslinkable functional group, ⁇ - methacryloxypropyl trimethysilane, ⁇ - methacryloxypropyl triethoxysilane, ⁇ - methacryloxypropyl trimethyl silane, 2 — Preferred are methacryloyloxyshettilysocyanate and glycidyl methacrylate, and ⁇ -methacryloxypropyl trimethoxysilane is a particularly preferred monomer.
- hydrophilic structural unit represented by the general formula (5) of the present invention examples include N, N'-disubstituted acrylamide, N-substituted acrylamide, N, N'-disubstituted methacrylamide, and N-substituted methacrylamide. it can.
- Preferred hydrophilic monomers in the present invention include N, N'-disubstituted acrylamide and N, N'-disubstituted methacrylamides, and particularly preferred hydrophilic monomers.
- N, N'—2g-substituted acrylamides include:
- preferred hydrophilic monomers in the present invention include N, N'-dimethylacrylamide, N-methylacrylamide, N, N'-ethylacetylolinoleamide, N-ethylacrylamide, and N-isopropylamine.
- particularly preferred hydrophilic monomers in the present invention include N, N'-dimethylacrylamide and N, N, 1'-ethylacrylamide. From an industrial viewpoint, N, '-dimethylacrylamide is the most preferred hydrophilic monomer in the present invention.
- a conventionally known polymerization reaction can be directly used.
- radical polymerization, ionic polymerization, coordination polymerization, polycondensation, or the like may be appropriately employed depending on the purpose, to synthesize a hydrophilic polymer having a required structure.
- the structure of the polymer chain formed by copolymerizing the hydrophobic monomer (including a monomer having a cross-linking functional group) of the present invention and a hydrophilic monomer may be random, alternating, graphite or block-like. Either may be used.
- a radical monomer or a hydrophilic monomer is formed by radical polymerization. It is also possible to employ a method of polymerizing a monomer in advance to synthesize a macromer, and then copolymerizing the macromer with the other hydrophobic monomer, such as Z or a hydrophilic monomer, as appropriate.
- the number average molecular weight of the polymer (component A) of the present invention is in the range of 1,000 to 1,000, preferably in the range of 500 to 800, and particularly preferably in the range. Is 20000 to 500.000. If the number average molecular weight is less than 100, the effects of the present invention will not be sufficiently exhibited, and long-term stability will be lost. On the other hand, if the number average molecular weight is more than 100,000, the solubility of the polymer decreases and the viscosity of the polymer in the dissolved state also increases significantly, which makes the manufacturing process of the blood filter difficult. The result is.
- the ratio of the hydrophobic structural units represented by the general formulas (1) to (4) in the polymer which is the component A of the present invention the hydrophobic structural unit of the general formulas (1) to (4) (general formula (1) 5)
- the hydrophilic structural unit + —the hydrophobic structural unit of the general formulas (1) to (4)) is preferably in the range of 0.5 to 99.5 mol%, more preferably in the range of 2 to 98 mol%. The range of 5 to 95 mol% is particularly preferred.
- hydrophobic structural unit is less than 0.5 mol% or more than 99.5 mol%, it is not possible to achieve both high leukocyte removal and efficient platelet recovery.
- the polymer (component A) of the present invention is preferably a hydrophilic polymer which is hydrophilic as a whole.
- the characteristics of the leukocyte removal filter of the present invention are not affected in the polymer main chain of the component A.
- an ether bond, an ester bond, an amide bond, an imide bond, a urethane bond It is not particularly limited to contain a structural unit having at least one bond selected from a sulfonic acid ester bond and a sulfide bond.
- the porous substrate (B component) in the present invention has a fine pore of multiple layers continuous from one surface to the other surface, and has a pore diameter capable of separating and removing leukocytes in the coexistence of the A component. It is a porous substrate. The shape and communication of the holes in the B component, the thickness, material, shape, dimensions, etc.
- the component B of the present invention can be used in any shape such as a fiber, a film, a sheet, a disk, a cylinder, a film, and a granule.
- the preferred average pore size of the component B required for the purpose of the present invention is in the range of 0.1 to ⁇ ⁇ ⁇ ⁇ ⁇ , and particularly preferably in the range of 0.5 to 50 ⁇ . It is particularly preferable that the thickness be in the range of 1 to 25 ⁇ m. When the average pore diameter is outside the range of 0 :! to 100 m, it is impossible to achieve both high leukocyte removal and efficient platelet high recovery.
- the average pore size in the component B of the present invention is a value measured and measured by a conventionally known method such as a mercury porosimeter or air permeability measurement.
- the specific surface area of the component B is also a very important factor for efficiently exhibiting the leukocyte removing ability of the present invention.
- the specific surface area is preferably in the range of 0.0 :! to 10.0 m 2 ng, more preferably in the range of 0.5 to 5.0 O in 2 Z g. More preferably, it is more preferably in the range of 0.8 to 3.0 m 2 / g. If the specific surface area is out of the range of the present invention, practical filtration characteristics as a blood filter cannot be obtained, and the value as a product will be low.
- the specific surface area of these B components is a value measured and calculated by a conventionally known method such as a specific surface area meter such as BET adsorption measurement or a mercury porosimeter.
- the porous substrate (B component) of the present invention has the above average pore diameter and specific surface area.
- the material is not particularly limited as long as it is a suitable material. That is, the material of the component B may be any of an organic material, an inorganic material, and an organic Z-inorganic composite material, and may be a natural material, a synthetic material, or a semi-synthetic material.
- a porous substrate formed from natural, synthetic, semi-synthetic, regenerated organic or inorganic fibers or composite fibers thereof, and a foam formed from organic or inorganic or composites thereof Foam, sponge, etc.
- a porous substrate made of an organic or inorganic material having pores formed by elution, decomposition, sintering, stretching, perforation, phase separation, or the like, or a composite thereof examples thereof include a porous substrate filled and / or bonded with fine particles or fine particles made of organic, inorganic, or a composite thereof.
- the properties of the fibers themselves are not particularly limited, for example, organic fibers or inorganic fibers, or short fibers, hollow fibers, or long fibers of the composite fibers thereof. Fibers and the like can be appropriately employed as needed.
- the form of the component B when formed from fibers may be any of a mere packed aggregate of fibers, a nonwoven fabric, a knitted fabric, and the like as long as the average pore diameter and the specific surface area are within the scope of the present invention.
- the fibers constituting the non-woven fabric have a fiber diameter of 0.1 to 10 ⁇ and a bulk density of 0.05 to lg Z cm 3. It is particularly preferable that the fiber diameter be 0.5 to 5 ⁇ and the bulk density be in the range of 0.1 to 0.8 gcm 3 in order to obtain the effects of the present invention.
- the A component is a B component. It must be as uniform as possible on the surface, including the porous interior of the Of the present invention achieves both high leukocyte removal and high platelet recovery at the time of whole blood filtration by the appropriate properties of the surface layer and the appropriate pore size formed from the A and B components. Is done.
- the ratio of the A component and the B component forming the leukocyte removal filter of the present invention is also one of the important factors for maximizing the effects of the present invention.
- the ratio of the polymer (A component) of the present invention to the porous substrate (B component) is preferably in the range of 0.001 to 1.0, and more preferably 0.001 to 1.0.
- the range of 0.8 is particularly preferred, and the most preferred range is 0.01 to 0.5.
- component A blocks the pores of component B, not only impairing the properties of the porous substrate, but also increasing the cost of the product. This is undesirable from an industrial point of view.
- the weight ratio of the A component to the B component is 0.001 or less, there is a possibility that a portion where the A component does not exist in the surface layer of the B component may occur. There is a possibility that the effects of the above cannot be fully exhibited.
- a preferred method for producing a product for achieving both high leukocyte-removing property and high platelet high-recovery property is a polymer having a hydrophobic structural unit of the present invention (A component).
- a solution (organic solution, aqueous solution, or a mixed solution thereof) containing, or the A component is made into a fluidized state by an appropriate method, and then impregnated or sprayed on the porous substrate (B component) of the present invention.
- the hydrophilic polymer (A component) can be made porous by a method of pumping the inside of the porous substrate (B component), or a method of applying the A component fine powder to the B component and then heating to dissolve the A component.
- a method of coating on the base material (component B) can be exemplified.
- these methods are not particularly limited to use in combination of a plurality of them.
- Prior art blood filter In one surface modification method, an extremely expensive and complicated apparatus and method such as electron beam irradiation and gamma irradiation were required.
- the surface layer of the component A can be easily present, and excellent performance as a leukocyte removal filter can be exhibited.
- a drying process such as blowing, a roll, and heating may be combined after the coating of the component A on the component B (including the surface layer: including the inside of the porous material).
- the hydrophobic structural unit of the component A of the present invention has a crosslinkable functional group
- the crosslinking reaction of the crosslinkable functional group can proceed in the coating step, drying step, heating step, or the like of the present invention
- the leukocyte removal filter having a crosslinked structure obtained by this manufacturing process can exhibit particularly preferable performance in the present invention.
- the A component contains one of a hydrophobic structural unit and a hydrophobic structural unit having a crosslinkable functional group, and the A component is coated on the B component,
- the blood filter in which a stable surface layer of the component A is formed on the component B by a cross-linking reaction, not only achieves both high leukocyte removal and efficient platelet recovery, as well as sterilization resistance and autoclaving resistance. It has excellent properties such as heat resistance (heat resistance) and long-term stability, and is the most preferred leukocyte removal filter in the present invention.
- the surface of the porous substrate (B component) (the surface in contact with each blood component) has A
- the presence of the component appears to be the most important factor.
- the hydrophobic structural unit By introducing the hydrophobic structural unit into the component A, the surface hydrophilicity of the polymer (component A) is slightly hydrophilicized while being hydrophilic, and the molecular characteristics such as hydrophobic interaction, which are advantageous for capturing leukocytes, are obtained. Probably obtained.
- component A the surface properties of the polymer (Component A) reduce the interaction with proteins in plasma, suppress the adsorption of plasma proteins that induce platelet activation to the filter surface, and increase the efficiency of platelets from whole blood. It is presumed that collection was realized. Of course, the right pore size plays an important role in the efficient removal of leukocytes from whole blood.
- the novel leukocyte removal filter of the present invention can be used not only effectively for whole blood, but also for selectively removing leukocytes from a platelet suspension containing various blood products or leukocytes.
- a platelet suspension containing various blood products or leukocytes There is no particular limitation on the use in the above.
- it may be used for removing leukocytes from a concentrated platelet solution obtained by centrifugation immediately after blood collection.
- the leukocyte-removing filter 1 of the present invention may be used in combination with a pre-filter for removing microaggregated components when filtering a whole blood or a platelet suspension mixed with leukocytes.
- the leukocyte removal filter of the present invention may be independently filled in the filter housing, but is incorporated in a blood component separation bag device in which a blood collection bag and a blood component separation bag are aseptically connected. It is also possible to use it.
- the polymerization reaction was carried out in the same manner as in Synthesis Example 1 except that the polymerization solvent was 15 mO1) and the polymerization solvent was N, N-dimethylformamide (DMF). After the reaction is completed,
- the polymerization reaction and analysis of the polymer were carried out in the same manner as in Synthesis Example 6, except that the monomer was changed to 8.8 g (0.7 mol) of ACM09 and 0.00.0 g (0.3 mol) of MMA.
- a polymerization reaction and analysis of a polymer were carried out in the same manner as in Synthesis Example 1 except that the amount was 3 g (0.994 mO 1).
- D MA A / B MA 0.4 / 99.6 (mol% ratio)
- a polymerization reaction and analysis of the polymer were carried out in the same manner as in Synthesis Example 1 except that the amount was 4 g (0.002 mol).
- the obtained polymer was a copolymer of DMAA / BMA-S9.60.4 (mo 1% ratio), and had Mn2950 and Mw7800. Was.
- PET polyethylene terephthalate
- the polymer obtained in Example 1 was immersed in 200 mL of an EtOH solution (polymer concentration: 5 wt%) for 3 minutes, and then sandwiched between nip rolls to remove excess polymer solution. For 5 hours to prepare a blood filter (A) coated with 16.3 wt% of polymer. .
- Coating amount, the coating amount (w t%) (post-coated nonwoven weight (g) - co over preparative prior nonwoven weight (g)) / Co over preparative prior nonwoven weight (g) X 1 0 0 Sand (A component ZB component weight ratio XI 00)
- the nonwoven fabric used in Production Example 1 was dissolved in the polymer obtained in Synthesis Example 4 in a water ZEtOH solution (2/8 volume ratio) to which dilute hydrochloric acid was added so that the concentration became 0.02 mo 1/1. Then, the polymer concentration was adjusted to 5 wt%. The polymer solution was immersed in 200 ml for 3 minutes, and then sandwiched between two rolls to remove excess polymer solution. The polymer solution was dried by heating at 80 for 1 hour. A coated blood filter (D) was prepared.
- a blood filter coated with 21.6 wt% polymer (E) was prepared in the same manner as in Production Example 4 except that the polymer obtained in Synthesis Example 5 was used. It was created.
- the nonwoven fabric used in Production Example 1 was immersed in 200 ml of a dioxane solution (polymer concentration: 5 wt%) of the polymer obtained in Synthesis Example 6 for 3 minutes. Next, the excess polymer solution was removed by being sandwiched between nip rolls, followed by vacuum drying at 40 for 5 hours to prepare a blood filter (F) coated with 22.0 wt% of the polymer.
- a blood filter (G) coated with 20.0 wt% of a polymer was prepared in the same manner as in Production Example 6, except that the polymer obtained in Synthesis Example 7 was used.
- the polymer obtained in Synthesis Example 8 was dissolved in a water / dioxane solution (2Z8 volume ratio) to which dilute hydrochloric acid was added so as to have a concentration of 0.000 mol mol, and the polymer concentration was adjusted to 5 wt%. Prepared.
- the polymer solution was immersed in 200 m ⁇ for 3 minutes. Next, after removing excess polymer solution by sandwiching it between nip rolls, it was heated and dried at 80 ° C. for 1 hour to prepare a blood filter (H) coated with 15.0 wt% of polymer.
- a blood filter (I) coated with 17.0 wt% of each polymer was prepared in the same manner as in Production Example 1 except that the polymer obtained in Synthesis Example 9 was used.
- a blood filter (L) coated with 19.0 wt% of a polymer was prepared in the same manner as in Production Example 4, except that the polymer obtained in Synthesis Example 12 was used.
- the fresh whole blood used is a CPD solution as an anticoagulant (composition: sodium 26.3 g / L citrate 3.27 g / L, glucose 23.2 g / L, phosphorus Sodium dihydrogen diacid dihydrate 2.5 1 g / L)
- CPD solution as an anticoagulant
- Whole blood prepared by collecting 100 ml of blood in a blood bag containing 14 ml, 20 ° C after blood collection, Using a syringe pump at room temperature at a flow rate of 2.7 ml / min, 6 ml was collected.
- the performance of the filter is indicated by the leukocyte removal ability (one log reduction) and the platelet recovery rate (%), and the leukocyte concentration and platelet concentration of the pre-filtration solution and the post-filtration solution are measured.
- the leukocyte concentration of the blood before filtration was measured by injecting a 10-fold diluted solution by the Turck method into a Bürker-Türk type hemocytometer, and using an optical microscope to measure the number of leukocytes present in the eight large sections. did.
- the leukocyte concentration of the filtered solution was measured by the Nadget method shown below. That is, after filtration, 1 ml of the blood is diluted and mixed 10-fold with Leucoplate (S0BI0DA), and then left at room temperature for 20 to 30 minutes. After separating leukocytes by centrifugation and removing the supernatant mixed with other blood components, the solution (undiluted) prepared in Leucoplate to make lmL again was added to the nadette calculation plate.
- Leukocyte counts were determined using an optical microscope.
- the platelet concentration was measured with an automatic Ik sphere counting device (Sysmex K450, Toa Medical Electronics Co., Ltd.).
- the hematocrit was measured using a hematocrit reader by placing blood in a glass capillary tube for micro blood test, centrifuging the blood, and using a hematocrit reader. [Blood evaluation method (2)]
- the polymer-coated nonwoven fabric or uncoated nonwoven fabric prepared in the manufacturing example is cut into a circular shape of 2 ⁇ each, and the polymer-coated nonwoven fabric 3 2 sheets (for the examples) or the uncoated nonwoven fabric 3 2 sheets (For Comparative Example 7)
- the column was stacked and packed in a Teflon-based column, and fresh human whole blood was flowed at a constant flow rate of 0.74 ml / min with a syringe pump to collect 13.3 ml.
- the performance of the filter is expressed as the leukocyte removal capacity (log reduction rate) and the platelet recovery rate (%), and the leukocyte concentration and platelet concentration of the pre-filtration solution and the post-filtration solution are measured.
- A leukocyte concentration before filtration
- B -leukocyte concentration after filtration
- C platelet concentration before filtration
- D platelet concentration after filtration
- leukocyte removal ability -L og (B — A)
- Platelet recovery -L og (
- the leukocyte concentration of the pre-filtration solution was measured using a residual leukocyte measurement reagent system LeucoC0UNT Tm kit (BD Bioscience, USA), a flow cytometer FACSCalibur (BD Bioscience, USA), and an analysis software CELL Quest (BD Bioscience, USA). It was used and measured. Platelet concentration was measured using an automatic hematology analyzer 3 ⁇ 4ftMAXM A / L-Retic. (BECKMAN COULTER, USA).
- Example 1 A (1) 56.4 / 43.6 16.3 1.4 78.0
- Example 3 C (2) 36.8 / 63.2 20.7 3.7 98.1
- Example 4 D (2) 95.9 / 4. 1 '24 .0 3.4 90.0
- Example 6 F (1) 83.9 / 16.1 22.0 1.2 84.6
- the present invention it is possible to provide a filter material for transmitting red blood cells, platelets, and plasma from a leukocyte-containing liquid typified by whole blood and selectively removing leukocyte components efficiently.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- External Artificial Organs (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01912245A EP1262204A4 (en) | 2000-03-10 | 2001-03-09 | NEW FILTER FOR LEUCOPHERESIS |
AU2001241085A AU2001241085A1 (en) | 2000-03-10 | 2001-03-09 | Novel leukapheretic filter |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000066683 | 2000-03-10 | ||
JP2000-66683 | 2000-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001066171A1 true WO2001066171A1 (fr) | 2001-09-13 |
Family
ID=18586004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/001880 WO2001066171A1 (fr) | 2000-03-10 | 2001-03-09 | Nouveau filtre pour leucopherese |
Country Status (4)
Country | Link |
---|---|
US (1) | US20030146150A1 (ja) |
EP (1) | EP1262204A4 (ja) |
AU (1) | AU2001241085A1 (ja) |
WO (1) | WO2001066171A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009018177A (ja) * | 2001-10-16 | 2009-01-29 | Asahi Kasei Kuraray Medical Co Ltd | ウイルス及び白血球選択除去材およびその使用 |
US8142717B2 (en) | 2007-04-23 | 2012-03-27 | Toyo Boseki Kabushiki Kaisha | Oxygenator of a hollow fiber membrane type |
US8236913B2 (en) | 2006-12-07 | 2012-08-07 | Toyo Boseki Kabushiki Kaisha | (Meth)acrylate copolymer, a method for producing the same and a medical device |
JP5136418B2 (ja) * | 2006-09-29 | 2013-02-06 | 東レ株式会社 | 細胞吸着カラム |
JP2014136724A (ja) * | 2013-01-16 | 2014-07-28 | Kao Corp | 非イオン性ポリマー |
CN105813663A (zh) * | 2013-12-13 | 2016-07-27 | 旭化成医疗株式会社 | 去除白血球的过滤材料、以及去除白血球的方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1493458B1 (en) | 2003-07-03 | 2007-01-17 | Fresenius Hemocare Italia S.r.l. | A filter for the removal of substances from blood products |
WO2010147621A1 (en) * | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Methods for ameliorating adverse effects associated with transfusion of aged red blood cells |
US20140367324A1 (en) * | 2013-06-15 | 2014-12-18 | Fenwal, Inc. | Coatings for biological fluid filters |
US10159778B2 (en) | 2014-03-24 | 2018-12-25 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
US10376627B2 (en) | 2014-03-24 | 2019-08-13 | Fenwal, Inc. | Flexible biological fluid filters |
US9968738B2 (en) | 2014-03-24 | 2018-05-15 | Fenwal, Inc. | Biological fluid filters with molded frame and methods for making such filters |
US9796166B2 (en) | 2014-03-24 | 2017-10-24 | Fenwal, Inc. | Flexible biological fluid filters |
US9782707B2 (en) | 2014-03-24 | 2017-10-10 | Fenwal, Inc. | Biological fluid filters having flexible walls and methods for making such filters |
CN216703954U (zh) * | 2020-06-23 | 2022-06-10 | 恩特格里斯公司 | 过滤器和多孔过滤膜 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0623042A (ja) * | 1991-09-27 | 1994-02-01 | Toyobo Co Ltd | 血液浄化吸着材および血液浄化方法 |
JPH1033668A (ja) * | 1996-07-23 | 1998-02-10 | Asahi Medical Co Ltd | 白血球選択除去フィルター及び白血球選択除去フィルター装置 |
JP2000051623A (ja) * | 1998-08-11 | 2000-02-22 | Terumo Corp | 血液フィルターおよびその製造方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871462A (en) * | 1985-12-23 | 1989-10-03 | Haemonetics Corporation | Enhanced separation of blood components |
WO1987005812A1 (en) * | 1986-03-28 | 1987-10-08 | Asahi Medical Co., Ltd. | Filter medium for selectively removing leucocytes |
US4976861A (en) * | 1987-10-20 | 1990-12-11 | Pall Corporation | Method for determining the wetting characteristic of a porous medium |
US4880548A (en) * | 1988-02-17 | 1989-11-14 | Pall Corporation | Device and method for separating leucocytes from platelet concentrate |
US5244578A (en) * | 1989-09-28 | 1993-09-14 | Terumo Kabushiki Kaisha | Blood plasma-separating membrane and blood plasma separator using the membrane |
US5217627A (en) * | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
US5407581A (en) * | 1992-03-17 | 1995-04-18 | Asahi Medical Co., Ltd. | Filter medium having a limited surface negative charge for treating a blood material |
EP0606646B1 (en) * | 1992-12-28 | 1997-09-24 | Asahi Medical Co., Ltd. | Filtermaterial, apparatus and method for removing leukocytes |
EP0856352B1 (en) * | 1995-10-09 | 2003-07-09 | Asahi Kasei Kabushiki Kaisha | Polysulfone membrane for purifying blood |
EP0923955B1 (en) * | 1997-12-17 | 2008-06-18 | Asahi Kasei Kuraray Medical Co., Ltd. | Manufacturing method of artificial organ, hollow fiber membrane, and dialyzer of hollow fiber membrane type |
-
2001
- 2001-03-09 EP EP01912245A patent/EP1262204A4/en not_active Withdrawn
- 2001-03-09 US US10/221,213 patent/US20030146150A1/en not_active Abandoned
- 2001-03-09 WO PCT/JP2001/001880 patent/WO2001066171A1/ja not_active Application Discontinuation
- 2001-03-09 AU AU2001241085A patent/AU2001241085A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0623042A (ja) * | 1991-09-27 | 1994-02-01 | Toyobo Co Ltd | 血液浄化吸着材および血液浄化方法 |
JPH1033668A (ja) * | 1996-07-23 | 1998-02-10 | Asahi Medical Co Ltd | 白血球選択除去フィルター及び白血球選択除去フィルター装置 |
JP2000051623A (ja) * | 1998-08-11 | 2000-02-22 | Terumo Corp | 血液フィルターおよびその製造方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009018177A (ja) * | 2001-10-16 | 2009-01-29 | Asahi Kasei Kuraray Medical Co Ltd | ウイルス及び白血球選択除去材およびその使用 |
CN100457200C (zh) * | 2001-10-16 | 2009-02-04 | 旭化成可乐丽医疗株式会社 | 病毒及白细胞选择除去材料 |
US7820371B2 (en) | 2001-10-16 | 2010-10-26 | Asahi Kasei Kuraray Medical Co., Ltd. | Method for removing viruses and leukocytes from blood using a surface comprising hydroxyl and polyethylene glycol groups |
JP5136418B2 (ja) * | 2006-09-29 | 2013-02-06 | 東レ株式会社 | 細胞吸着カラム |
US8236913B2 (en) | 2006-12-07 | 2012-08-07 | Toyo Boseki Kabushiki Kaisha | (Meth)acrylate copolymer, a method for producing the same and a medical device |
US8142717B2 (en) | 2007-04-23 | 2012-03-27 | Toyo Boseki Kabushiki Kaisha | Oxygenator of a hollow fiber membrane type |
JP2014136724A (ja) * | 2013-01-16 | 2014-07-28 | Kao Corp | 非イオン性ポリマー |
CN105813663A (zh) * | 2013-12-13 | 2016-07-27 | 旭化成医疗株式会社 | 去除白血球的过滤材料、以及去除白血球的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1262204A1 (en) | 2002-12-04 |
US20030146150A1 (en) | 2003-08-07 |
AU2001241085A1 (en) | 2001-09-17 |
EP1262204A4 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002355687B2 (en) | Polymer for coating leukocyte removal filter material and filter material | |
Ran et al. | Biocompatibility of modified polyethersulfone membranes by blending an amphiphilic triblock co-polymer of poly (vinyl pyrrolidone)–b-poly (methyl methacrylate)–b-poly (vinyl pyrrolidone) | |
US11020521B2 (en) | Hemocompatibility modifiers for cross-linked polymeric material | |
WO2001066171A1 (fr) | Nouveau filtre pour leucopherese | |
JP4587213B2 (ja) | 生体適合性ポリマーおよびそれを用いた白血球選択除去フィルター材 | |
JP4271265B2 (ja) | 白血球除去フィルター材 | |
JP7085533B2 (ja) | 官能化コポリマー及びその使用 | |
Shen et al. | Preliminary investigation on hemocompatibility of poly (vinylidene fluoride) membrane grafted with acryloylmorpholine via ATRP | |
JP6752605B2 (ja) | 生体由来液処理フィルター及びフィルターデバイス | |
US8815350B2 (en) | Method for grafting a porous element for leucodepletion | |
JP2002030125A (ja) | 新規親水化芳香族高分子 | |
TWI711470B (zh) | 血液處理用珠粒 | |
CN112827478B (zh) | 血液处理用珠 | |
JPH06312017A (ja) | エンドトキシン及び/又はサイトカインの吸着材及び該吸着材を用いた浄化血液の取得方法 | |
JP2006077136A (ja) | 生体適合性ポリマーの製造方法 | |
CN118103491A (zh) | 收获生物制剂的方法 | |
JP2001300221A (ja) | 白血球除去用フィルター材及び該フィルター用ポリマー | |
WO2023037178A1 (en) | Method of harvesting biologics | |
JPH07289633A (ja) | 除去器及び除去装置 | |
WO2024074906A1 (en) | Anion exchange separation article, methods of making, and methods of using | |
CN108786746A (zh) | 一种用于选择性净化血液的医疗材料及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564823 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10221213 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001912245 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001912245 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001912245 Country of ref document: EP |